| 1 |
刘占祥. 移植后淋巴细胞增殖性疾病诊断进展与治疗规范[J]. 白血病淋巴瘤，2017，26(8)：502-505.
|
| 2 |
Kotton CN, Huprikar S, Kumar D. Transplant infectious diseases: a review of the scientific registry of transplant recipients published data[J]. Am J Transplant, 2017, 17(6): 1439-1446.
|
| 3 |
Timuragaoglu A, Ugur-Bilgin A, Colak D, et al. Posttransplant lymphoproliferative disorders in transplant recipients[J]. Transplant Proc, 2006, 38(2): 641-645.
|
| 4 |
Singavi AK, Harington AM, Fenske TS. Post-transplant lymphoproliferative disorders[J]. Cancer Treat Res, 2015, 165: 305-327.
|
| 5 |
Francis A, Johnson DW, Craig J, et al. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients[J]. Kidney Int, 2018, 94(4): 809-817.
|
| 6 |
Akar Özkan E, Özdemir BH, Deniz EE, et al. Posttransplant lymphoproliferative disorder after liver and kidney transplant[J]. Exp Clin Transplant, 2014, 12 (Suppl 1): S142-S148.
|
| 7 |
Dierickx D, Touseyn T, Gheysens O. How treat post-transplant lymphoproliferative disorders[J]. Blood, 2015, 126(20): 2274-2283.
|
| 8 |
Nijland ML, Kersten MJ, Pals ST, et al. Epstein-Barr virus-positive post-transplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations，diagnosis and management[J]．Transplant Direct, 2015, 15, 2(1): e48.
|
| 9 |
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients[J]. JAMA，2011，306(17)：1891-1901.
|
| 10 |
Gwon JG, Kim YH, Han DJ. Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000[J]. Asian J Surg, 2018, 42(4): 551-556.
|
| 11 |
Ready E, Chernushkin K, Partovi N, et al. Post-transplant lymphoproliferative disorder in adults receiving kidney transplantation in britishcolumbia: a retrospective cohort analysis[J]. Can J Kidney Health Dis, 2018, 5: 2054358118760831.
|
| 12 |
Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018, 378(6): 549-562.
|
| 13 |
卢峡，郭晖，明长生，等. 肾移植术后淋巴细胞增殖性疾病三例报道[J]. 中华器官移植杂志，2018, 39(9): 559-561.
|
| 14 |
陈雁扬，陈国栋，王珏，等. 肾移植术后淋巴组织增生性疾病一例报告暨文献复习[J]. 中华肾脏病杂志，2018, 34 (1): 24-29.
|
| 15 |
王照明，郑树森，丁伟，等. 移植后淋巴增生性疾病六例临床病理分析[J]. 中华血液学杂志，2007, 28(8): 514-518.
|
| 16 |
宋少伟，张佳林，吴刚，等. 肾移植术后淋巴增生性疾病的诊治二例[J]. 中华器官移植杂志，2007, 28(11): 696-697.
|
| 17 |
吴轲，宫念樵，明长生，等. 肾移植术后发生淋巴细胞增生性疾病一例[J]. 中华器官移植杂志，2007, 28(12): 758.
|
| 18 |
Shustik C, Jamison BM, Alfieri C, et al. A solitary plasma-cytoma of donor origin arising 14 years after kidney allotransplantation[J]. Br J Haematol, 1995，91(1)：167-168.
|
| 19 |
Meehan SM, Domer P, Josephson M, et al. The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies[J]. Hum Pathol, 2001, 32(2)：205-215.
|
| 20 |
Kuppachi S, Naina HV, Self S, et al. Plasmacytoma-like post-transplantation lymphoproliferative disorder confined to the renal allograft: a case report[J]. Transplant Proc, 2013, 45(7)：2791-2794.
|
| 21 |
Thibaud V, Rivalan J, Llamas F, et al. Plasmacytoma-like post-kidney-transplant lymphoproliferative disorder confined to renal allograft and urinary tract: a case report[J]. Ne phrol Ther, 2018, 14(7): 544-547.
|
| 22 |
Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage[J]. Oncotarget, 2015, 6(32): 33849-33866.
|
| 23 |
Morscio J, Tousseyn T. Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders[J]. World J Transplant, 2016, 6(3): 505-516.
|
| 24 |
Susanne WL, Jenny KL, Hansson S, et al. Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients[J]. Pediatr Nephrol, 2020, 35(3): 427-439.
|
| 25 |
Lee KF, Tsai YT, Lin CY, et al. Cancer incidence among heart, kidney, and liver transplant recipients in Taiwan[J]. PLoS One, 2016, 11 (5): e0155602
|
| 26 |
Sebelin-Wulf K, Nguyen TD, Oertel S, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD[J]. Transpl Immunol，2007，17(3)：203-210.
|
| 27 |
Ruf S, Behnke-Hall K, Gruhn B, et al. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation[J]. J Clin Virol, 2012, 53(3): 186-194.
|
| 28 |
Doak PB, Montgomerie JZ, North JD, et al. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy[J]. R Med J，1968，21(4)：746-768.
|
| 29 |
Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN guidelines insights: B-cell lymphomas, version 3.2019[J]. J Natl Compr Canc Netw, 2019, 17(6)：650-661.
|
| 30 |
Taylor E, Jones M, Hourigan MJ, et al. Cesation of immunosuppression duringchemotherapyfor post-transplant lymphoproliferative disorders in renal transplant patients[J]. Nephrol Dial Transplant, 2015, 30(10): 1774-1779.
|
| 31 |
Kanzelmeyer NK, Maecker-Kolhoff B, Zierhut H, et al. Graft outcomes following diagnosis of posttransplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study[J]. Transpl Int, 2018, 31(4): 367-376.
|
| 32 |
EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment[J]. Nephrol Dial Transplant, 2002，17 (Suppl 4): S31-S33, S35-S36.
|
| 33 |
Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled，muhicenter，open-label study in China[J]. Clin Cancer Res, 2016, 22(21): 5223-5228.
|
| 34 |
Shi Y, Jia B, Xu W, et al.Chidamide in relapsed or refractory peripheral T cell lymphoma：amuhieenter real-world study in China[J]. J Hematol Oncol, 2017, 15, 10(1)：69.
|
| 35 |
Francis A, Johnson DW, Craig J，et al. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients[J]. Kidney Int，2018, 94(4): 809-817.
|
| 36 |
Morton M, Coupes B, Ritchie J, et al.Post-transplant lymphoproliferative disorder in adult renal transplant recipients：survival and prognosis[J]. Leuk Lymphoma, 2016, 57(2): 299-305.
|
| 37 |
Montanari F, Radeski D, Seshan V, et al. Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series[J]. Br J Haematol, 2015, 171(4): 491-500.
|
| 38 |
Trappe RU, Choquet S, Dierickx D, et al. International pognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-Positive B cell PTLD：clues from the PTLD-1 trial[J]. Am J Transplant, 2015, 15(4): 1091-1100.
|